Navigoe Wealth Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Navigoe Wealth Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	+1	New	+$37	﹤0.01%	597

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Navigoe Wealth Management's CRNX Position: Q2 2026 in Review

Navigoe Wealth Management opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #597 among its holdings.

266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Navigoe Wealth Management held 1 share of Crinetics Pharmaceuticals worth $0 as of Q2 2026.
Crinetics Pharmaceuticals was a new Navigoe Wealth Management position in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of Navigoe Wealth Management's portfolio in Q2 2026, its #597 holding.
266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Navigoe Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.